Search
JB991
go.drugbank.com/drugs/DB05081ExperimentalJB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis.
VSF-173
go.drugbank.com/drugs/DB05753InvestigationalIt is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.
Tosufloxacin
go.drugbank.com/drugs/DB16850ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePirisudanol
go.drugbank.com/drugs/DB13412ExperimentalCategories: Psychostimulants, Agents Used for ADHD and NootropicsCarvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigationalCarvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunct...
Categories: Antihypertensive Agents Indicated for Hypertension, Compounds used in a research, industrial, or household settingHexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478].
Ingenol disoxate
go.drugbank.com/drugs/DB15109InvestigationalIngenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk
Nigella sativa oil
go.drugbank.com/drugs/DB28165InvestigationalNigella Sativa Oil is under investigation in clinical trial NCT06823544 (A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis
Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalCurrently, ramosetron is only approved for use Japan and in certain Southeast Asian countries.
Fenofibrate
go.drugbank.com/drugs/DB01039ApprovedInvestigationalFenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. Fenofibrate was granted FDA approval on 31 December 1993.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia